Guggenheim Keeps Their Buy Rating on Unicycive Therapeutics (UNCY)
I'm PortAI, I can summarize articles.
Guggenheim analyst Vamil Divan has reiterated a Buy rating on Unicycive Therapeutics (UNCY) with a price target of $46.00, while the stock closed at $5.93. The overall analyst consensus for Unicycive is a Strong Buy, with an average price target of $35.80, indicating a potential upside of 503.71%. Additionally, Maxim Group also maintains a Buy rating with a $30.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments